Advertisement

Topics

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Patients With Schizophrenia and Schizoaffective Disorder

2015-04-28 14:31:40 | BioPortfolio

Published on BioPortfolio: 2015-04-28T14:31:40-0400

Clinical Trials [3256 Associated Clinical Trials listed on BioPortfolio]

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of s...

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms ...

A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs

The purpose of this study is to see if differences exist in outcome in patients with schizophrenia or schizoaffective disorder who were switched from other antipsychotics to ziprasidone.

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medicati...

A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with persis tent, predominant negative ...

PubMed Articles [18341 Associated PubMed Articles listed on BioPortfolio]

Instrument-based assessment of motor function yields no evidence of dyskinesia in adult first-degree biological relatives of individuals with schizophrenia and schizoaffective disorder.

There is accruing evidence of spontaneous dyskinesia in individuals with schizophrenia that is independent of medication exposure. Dyskinetic motor behavior is also present in individuals who are at h...

An evaluation of the differences in DNA damage in lymphocytes and repair efficiencies in patients with schizophrenia and schizoaffective disorder.

Schizophrenia and schizoaffective disorder are chronic and debilitating psychiatric disorders. The present study was designed to determine DNA damage in patients with schizophrenia and schizoaffective...

Does Schizoaffective Disorder explain the mental illnesses of Robert Schumann and Vincent Van Gogh?

The geniuses Robert Schumann and Vincent Van Gogh show striking similarities both in the longitudinal nature of the progression of their illnesses, and the symptoms they experienced. There have been p...

Service utilization and suicide among people with schizophrenia spectrum disorders.

To compare individuals with and without schizophrenia spectrum disorders (SSD) (schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified) who die by suicide.

EEG coherence in a mental arithmetic task performance in first episode schizophrenia and schizoaffective disorder.

To evaluate the coherence values of the cortical bands in patients with first episode schizophrenia and schizoaffective disorder during the performance of a mental arithmetic task.

Medical and Biotech [MESH] Definitions

A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in MENTAL RETARDATION and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)

One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

A benzocycloheptapyridoisoquinolinol that has been used as an antipsychotic, especially in schizophrenia.

An antipsychotic agent used in schizophrenia.

More From BioPortfolio on "A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Patients With Schizophrenia and Schizoaffective Disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial